-
公开(公告)号:US6114372A
公开(公告)日:2000-09-05
申请号:US155695
申请日:1998-10-02
申请人: Andrew Douglas Baxter , David Alan Owen , John Gary Montana , Robert John Watson , John Fraser Keily
发明人: Andrew Douglas Baxter , David Alan Owen , John Gary Montana , Robert John Watson , John Fraser Keily
IPC分类号: A61K31/00 , A61K31/18 , A61K31/40 , A61K31/403 , A61K31/4035 , A61P1/00 , A61P9/00 , A61P17/00 , A61P25/00 , A61P25/04 , A61P27/00 , A61P29/00 , A61P35/00 , A61P43/00 , C07C323/60 , C07C327/32 , C07D209/48 , A61K31/22 , C07D323/60
CPC分类号: C07D209/48 , C07C323/60 , C07C327/32
摘要: Compounds of formula (I) having MMP and TNF inhibitory activity. ##STR1##
摘要翻译: PCT No.PCT / GB97 / 00957 Sec。 371日期:1998年10月2日 102(e)1998年10月2日PCT PCT 1997年4月4日PCT公布。 公开号WO97 / 37973 日期:1997年10月16日具有MMP和TNF抑制活性的式(I)化合物。
-
12.Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity 失效
标题翻译: 具有MMP和TNF抑制活性的羟肟酸和羧酸衍生物公开(公告)号:US6118001A
公开(公告)日:2000-09-12
申请号:US908397
申请日:1997-08-07
申请人: David Alan Owen , John Gary Montana , John Fraser Keily , Robert John Watson , Andrew Douglas Baxter
发明人: David Alan Owen , John Gary Montana , John Fraser Keily , Robert John Watson , Andrew Douglas Baxter
IPC分类号: C07D233/74 , A61K31/16 , A61K31/19 , A61K31/215 , A61K31/341 , A61K31/36 , A61K31/366 , A61K31/381 , A61K31/4035 , A61K31/4164 , A61K31/4166 , A61K31/426 , A61K31/4402 , A61K31/4409 , A61K31/445 , A61K31/47 , A61K31/50 , A61K31/502 , A61P17/00 , A61P27/14 , A61P29/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07C317/44 , C07D207/48 , C07D209/48 , C07D211/54 , C07D213/50 , C07D213/55 , C07D213/71 , C07D215/36 , C07D233/84 , C07D237/14 , C07D237/32 , C07D277/20 , C07D277/36 , C07D307/38 , C07D309/08 , C07D317/62 , C07D333/22 , C07D211/96 , C07D235/02 , C07D237/04
CPC分类号: C07C317/44 , C07D207/48 , C07C2101/08
摘要: Disclosed are hydroxamic and carboxylic acid derivatives which are useful inhibitors of matrix metalloproteinase and/or TNF.alpha.-mediated diseases, including degenerative diseases and certain cancers.
摘要翻译: 公开的是异羟肟酸和羧酸衍生物,其是用于基质金属蛋白酶和/或TNFα介导的疾病的有用的抑制剂,包括退行性疾病和某些癌症。
-
公开(公告)号:US6090840A
公开(公告)日:2000-07-18
申请号:US155696
申请日:1998-10-05
申请人: Andrew Douglas Baxter , David Alan Owen , John Gary Montana , Robert John Watson , John Fraser Keily
发明人: Andrew Douglas Baxter , David Alan Owen , John Gary Montana , Robert John Watson , John Fraser Keily
IPC分类号: C07D209/48 , A61K31/00 , A61K31/165 , A61K31/40 , A61K31/403 , A61K31/4035 , A61P1/00 , A61P9/00 , A61P17/00 , A61P25/00 , A61P25/04 , A61P27/00 , A61P29/00 , A61P35/00 , A61P43/00 , C07C323/60 , C07C327/32
CPC分类号: C07C323/60 , C07C327/32
摘要: The subject invention concerns mercaptoalkylacyl compounds of formula (I): ##STR1## The compounds of the subject invention can be used to inhibit matrix metalloproteinases and/or TNF.alpha.- and L-selectin sheddase-mediated diseases including degenerative diseases and cancers. The subject invention also concerns methods of using the compounds of the invention to treat or prevent conditions associated with matrix metalloproteinases or that are mediated by TNF.alpha. or L-selectin sheddase.
摘要翻译: PCT No.PCT / GB97 / 00959 Sec。 371日期:1998年10月5日 102(e)日期1998年10月5日PCT 1997年4月4日PCT公布。 公开号WO97 / 37974 日期为1997年10月16日本发明涉及式(I)的巯基烷基酰基化合物:本发明的化合物可用于抑制基质金属蛋白酶和/或TNFα-和L-选择蛋白脱落酶介导的疾病,包括退行性疾病和癌症。 本发明还涉及使用本发明化合物治疗或预防与基质金属蛋白酶相关或由TNFα或L-选择素脱落酶介导的病症的方法。
-
公开(公告)号:US06455531B1
公开(公告)日:2002-09-24
申请号:US09806259
申请日:2001-03-28
申请人: David Alan Owen , Andrew Douglas Baxter , Robert John Watson , Duncan Robert Hannah , John Gary Montana
发明人: David Alan Owen , Andrew Douglas Baxter , Robert John Watson , Duncan Robert Hannah , John Gary Montana
IPC分类号: A61K314453
CPC分类号: C07D295/185 , C07C259/06 , C07C259/08 , C07C2601/04 , C07C2601/14 , C07C2602/08 , C07D211/32 , C07D211/46 , C07D211/54 , C07D295/135 , C07D413/04
摘要: Compounds having therapeutic utility are of the formula wherein NB2 is heterocycloalkyl and R1 and R2 are each various substituents or a cyclic group.
摘要翻译: 具有治疗效用的化合物是其中NB2是杂环烷基并且R 1和R 2各自是各种取代基或环状基团。
-
15.Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity 失效
标题翻译: 具有MMP和TNF抑制活性的羟肟酸和羧酸衍生物公开(公告)号:US06187924B1
公开(公告)日:2001-02-13
申请号:US09190774
申请日:1998-11-12
IPC分类号: C07D30733
CPC分类号: C07D405/12 , C07C311/04 , C07D211/96 , C07D233/72 , C07D309/08 , C07D405/14
摘要: Compounds of formula (I) are useful as therapeutic agents, by virtue of having MMP and TNF inhibitory activity.
摘要翻译: 由于具有MMP和TNF抑制活性,式(I)化合物可用作治疗剂。
-
公开(公告)号:US06506764B1
公开(公告)日:2003-01-14
申请号:US09623669
申请日:2000-09-06
IPC分类号: A61K31438
CPC分类号: C07D221/20 , C07D211/96
摘要: Compounds of the formula B—X—(CH2)m—CR1R2—(CH2)n—CO—Y (I) have therapeutic utility as inhibitors of metalloproteinases etc.
摘要翻译: 具有治疗作用的化合物作为金属蛋白酶抑制剂等
-
公开(公告)号:US6100266A
公开(公告)日:2000-08-08
申请号:US239603
申请日:1999-01-29
IPC分类号: C07D295/22 , A61K31/19 , A61K31/192 , A61K31/495 , A61P1/02 , A61P1/04 , A61P1/14 , A61P7/02 , A61P7/04 , A61P9/00 , A61P9/08 , A61P9/10 , A61P11/06 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P25/06 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P35/00 , A61P35/04 , A61P37/06 , C07C20060101 , C07C317/44 , C07C317/46 , A61K31/38 , A61K31/44 , A61K31/455
CPC分类号: C07C317/44 , C07C317/46
摘要: For the treatment of cancer, inflammation, and other conditions associated with matrix metalloproteinases or that are mediated by TNF.alpha. or enzymes involved in the shedding of L-selectin, CD23, the TNF receptors, IL-1 receptors, or IL-6 receptors, disclosed are compounds of the general formulaB--X--(CH.sub.2).sub.m --(CR.sup.1 R.sup.2).sub.n --W--COY.
摘要翻译: 为了治疗与基质金属蛋白酶有关的癌症,炎症和其它与TNF-α或参与L-选择蛋白,CD23,TNF受体,IL-1受体或IL-6受体脱落酶相关的病症, 公开了通式BX-(CH2)m-(CR1R2)nW-COY的化合物。
-
18.Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity 失效
标题翻译: 具有MMP和TNF抑制活性的羟肟酸和羧酸衍生物公开(公告)号:US06310088B1
公开(公告)日:2001-10-30
申请号:US09564217
申请日:2000-05-04
IPC分类号: C07D33360
CPC分类号: C07D333/60
摘要: Compounds of formula (I) are useful therapeutic agents, by virtue of having MMP and TNF inhibitory activity.
摘要翻译: 由于具有MMP和TNF抑制活性,式(I)化合物是有用的治疗剂。
-
公开(公告)号:US5994293A
公开(公告)日:1999-11-30
申请号:US644381
申请日:1996-05-10
IPC分类号: A61K38/00 , A61P1/00 , A61P1/02 , A61P9/10 , A61P17/00 , A61P25/00 , A61P25/28 , A61P27/02 , A61P27/14 , A61P27/16 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D209/48 , C07D403/12 , C07K5/02 , C07K5/03 , C07K5/00 , A61K38/05
CPC分类号: C07D209/48 , C07D403/12 , C07K5/0207 , A61K38/00 , Y10S530/868
摘要: Dipeptidyl derivatives having a SH of acylS group and which are amides, thioamides or S(O).sub.0-2 -amides, have therapeutic utility via MMP or TNF inhibition.
摘要翻译: 具有酰基S的SH并且是酰胺,硫代酰胺或S(O)0-2-酰胺)的二肽基衍生物通过MMP或TNF抑制具有治疗效用。
-
公开(公告)号:US6063786A
公开(公告)日:2000-05-16
申请号:US190546
申请日:1998-11-12
IPC分类号: C07D239/22 , A61K31/513
CPC分类号: C07D239/22
摘要: Compounds of formula (I) ##STR1## are useful as therapeutic agents, by virtue of having MMP and TNF inhibitory activity.
摘要翻译: 由于具有MMP和TNF抑制活性,式(I)化合物可用作治疗剂。
-
-
-
-
-
-
-
-
-